Mirtel (Mirtazapine)

Mirtazapine works by blocking central presynaptic alpha‑2 adrenergic receptors, which increases the release of norepinephrine. It also antagonizes postsynaptic 5‑HT2, 5‑HT3 and H1 receptors, enhancing serotonergic transmission while reducing certain side‑effects associated with serotonin excess.

The appropriate dose of Mirtel is determined by the prescribing clinician based on the individual’s medical condition, response to therapy, and tolerability. Dosage adjustments are made according to clinical judgment and patient needs.

Safety of mirtazapine in pregnancy or while breastfeeding has not been fully established. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under close medical supervision.

To order Mirtel, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and necessary import documentation.

Mirtel (mirtazapine) belongs to the NaSSA class, differing from SSRIs and SNRIs by its dual antagonism of alpha‑2 adrenergic and specific serotonin receptors. This mechanism often results in a distinct side‑effect profile, such as higher sedation and appetite increase, which may be advantageous or limiting compared with other antidepressants.

Mirtel should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original container, protect them from moisture, heat and direct light to maintain stability throughout the shelf life.

Mirtel is taken orally, usually once daily in the evening with or without food, as directed by the prescribing healthcare professional. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed.

Serious risks include the potential for agranulocytosis, severe hypotension, seizures, serotonin syndrome when combined with other serotonergic drugs, and emergence of suicidal thoughts, particularly during the initial treatment period. Prompt medical attention is required if any of these occur.

Mirtel is contraindicated in patients with known hypersensitivity to mirtazapine or any of its excipients, those currently taking monoamine oxidase inhibitors, or individuals with severe hepatic impairment without appropriate dose adjustment. Clinicians should also exercise caution in patients with a history of bipolar disorder or uncontrolled cardiovascular disease.